Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology
Published in: Clinical Research in Cardiology 4/2011

01-04-2011 | Original Paper

Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure

Authors: Michael Behnes, Ursula Hoffmann, Siegfried Lang, Christel Weiss, Parviz Ahmad-Nejad, Michael Neumaier, Martin Borggrefe, Martina Brueckmann

Published in: Clinical Research in Cardiology | Issue 4/2011

Login to get access

Abstract

Purpose

Atrial fibrillation (AF) and acute congestive heart failure (aCHF) are characterized by an adverse cardiac remodeling. Arrhythmogenic or structural remodeling can be caused by interstitial fibrosis. Transforming growth factor beta 1 (TGF-beta 1) represents a central regulator of cardiac fibrosis. This study investigates serum levels of TGF-beta 1 in patients with AF and aCHF.

Methods

401 patients presenting with symptoms of dyspnea or peripheral edema were prospectively enrolled. Blood samples for measurement of TGF-beta 1 (R&D Systems, Inc.) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) (DadeBehring ltd.) were collected after the initial clinical evaluation.

Results

Median TGF-beta 1 levels were lower in patients with AF (21.0 ng/ml, interquartile range (IR) 15.4–27.6 ng/ml, n = 107) compared to those without (25.0 ng/ml, IR 18.5–31.6 ng/ml, n = 294) (p = 0.009). Patients with aCHF had lower TGF-beta 1 levels (median 22.0 ng/ml, IR 15.6–27.1 ng/ml, n = 122) than those without (median 24.9 ng/ml, IR 18.1–31.9 ng/ml, n = 279) (p = 0.0005). In logistic regression models TGF-beta 1 was still associated with AF (odds ratio (OR) 3.00, 95% CI 1.37–6.61, p = 0.0001) and aCHF (OR 3.98, 95% CI 1.55–10.19, p = 0.004). TGF-beta 1 inversely correlated with left atrial diameter (r = −0.30, p = 0.007) and NT-proBNP (r = −0.14, p = 0.007).

Conclusions

Low serum levels of TGF-beta 1 are associated with AF and aCHF. This decrease may result from a higher consumption of TGF-beta 1 within the impaired myocardium or antifibrotic functions of natriuretic peptides.
Literature
1.
Kirchhof P, Bax J, Blomstrom-Lundquist C et al (2009) Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled ‘research perspectives in atrial fibrillation’. Europace 11:860–885PubMedCrossRef
2.
Horlitz M, Schley P, Shin DI et al (2008) Atrial tachycardias following circumferential pulmonary vein ablation: observations during catheter ablation. Clin Res Cardiol 97:124–130PubMedCrossRef
3.
Nitardy A, Langreck H, Dietz R et al (2009) Reduction of right ventricular pacing in patients with sinus node dysfunction through programming a long atrioventricular delay along with the DDIR mode. Clin Res Cardiol 98:25–32PubMedCrossRef
4.
Hauck M, Bauer A, Voss F et al (2009) Effect of cardiac resynchronization therapy on conversion of persistent atrial fibrillation to sinus rhythm. Clin Res Cardiol 98:189–194PubMedCrossRef
5.
Tebbe U, Oeckinghaus R, Appel KF et al (2008) AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation. Clin Res Cardiol 97:389–396PubMedCrossRef
6.
Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373:155–166PubMedCrossRef
7.
Opie LH, Commerford PJ, Gersh BJ et al (2006) Controversies in ventricular remodelling. Lancet 367:356–367PubMedCrossRef
8.
Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442
9.
Dagli N, Karaca I, Yavuzkir M et al (2008) Are maximum P wave duration and P wave dispersion a marker of target organ damage in the hypertensive population? Clin Res Cardiol 97:98–104PubMedCrossRef
10.
Plisiene J, Blumberg A, Haager G et al (2008) Moderate physical exercise: a simplified approach for ventricular rate control in older patients with atrial fibrillation. Clin Res Cardiol 97:820–826PubMedCrossRef
11.
12.
Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedCrossRef
13.
Akinci B, Bayraktar F, Saklamaz A et al (2007) Low transforming growth factor-beta1 serum levels in idiopathic male osteoporosis. J Endocrinol Invest 30:350–355PubMed
14.
Stefoni S, Cianciolo G, Donati G et al (2002) Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 61:324–335PubMedCrossRef
15.
Gordon KJ, Blobe GC (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197–228PubMed
16.
Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118:10–24PubMedCrossRef
17.
Clarke DC, Liu X (2008) Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol 18:430–442PubMedCrossRef
18.
Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96:4065–4082PubMed
19.
Behnes M, Brueckmann M, Ahmad-Nejad P et al (2009) Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol 135:165–174PubMedCrossRef
20.
Behnes M, Lang S, Breithardt OA et al (2008) Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema. J Heart Valve Dis 17:557–565PubMed
21.
Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429
22.
Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed
23.
Corda S, Samuel JL, Rappaport L (2000) Extracellular matrix and growth factors during heart growth. Heart Fail Rev 5:119–130PubMedCrossRef
24.
Leask A (2007) TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 74:207–212PubMedCrossRef
25.
Zeisberg EM, Tarnavski O, Zeisberg M et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952–961PubMedCrossRef
26.
Xiao H, Zhang YY (2008) Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol 35:335–341PubMedCrossRef
27.
Everett THt, Olgin JE (2007) Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4:S24–S27PubMedCrossRef
28.
Li X, Ma C, Dong J et al (2008) The fibrosis and atrial fibrillation: is the transforming growth factor-beta(1) a candidate etiology of atrial fibrillation. Med Hypotheses 70:317–319PubMedCrossRef
29.
Lim H, Zhu YZ (2006) Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 63:2584–2596PubMedCrossRef
30.
MacLellan WR (2000) Advances in the molecular mechanisms of heart failure. Curr Opin Cardiol 15:128–135PubMedCrossRef
31.
Xu J, Cui G, Esmailian F et al (2004) Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109:363–368PubMedCrossRef
32.
Lin CS, Pan CH (2008) Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65:1489–1508PubMedCrossRef
33.
Du J, Xie J, Zhang Z et al (2010) TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation. Circ Res 106:992–1003
34.
Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318–328PubMedCrossRef
35.
Ogawa Y, Tamura N, Chusho H et al (2001) Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 79:723–729PubMedCrossRef
36.
Letsas KP, Filippatos GS, Pappas LK et al (2009) Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol 98:101–106PubMedCrossRef
37.
Li P, Wang D, Lucas J et al (2008) Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 102:185–192PubMedCrossRef
38.
39.
Dobrev D (2010) Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn Schmiedebergs Arch Pharmacol 381:195–206PubMedCrossRef
40.
Dobrev D,Nattel S (2008) Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 52:293–299PubMedCrossRef
Metadata
Title
Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure
Authors
Michael Behnes
Ursula Hoffmann
Siegfried Lang
Christel Weiss
Parviz Ahmad-Nejad
Michael Neumaier
Martin Borggrefe
Martina Brueckmann
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 4/2011
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0248-1

Other articles of this Issue 4/2011

Clinical Research in Cardiology 4/2011 Go to the issue

Original Paper

Time course of right ventricular functional parameters after surgical correction of tetralogy of Fallot determined by cardiac magnetic resonance

Original Paper

Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry)

Letter to the Editors

PMS: premenstrual storm? An unusual cause of electrical storm in a young woman with vasospastic angina

Letter to the Editors

Acquired long QT interval in a recurrent septic female patient with polymorphic ventricular tachycardia due to primary acute adrenal insufficiency

Laudatio

In honor of Professor Dr. med. Gerhard Riecker on his 85th birthday

Letter to the Editors

Acute cardiac arrest secondary to severe hyperkalemia due to autoimmune polyendocrine syndrome type II